Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women

Cagnacci, Angelo; Generali, Matteo; Pirillo, Debora; Baldassari, Francesco; Volpe, Annibale

doi:10.1080/13697130600870352

Cited by 10 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SMD was −0.27 (95% CI −0.54 to −0.01, I 2 = 72.6%) in studies with a dosage <100 mg day −1 . It was previously reported that post‐methionine loading homocysteine levels were more significantly reduced with a lower dosage of oestrogens . Dosage might be one factor influencing the effect of isoflavones on serum homocysteine levels.…”

Section: Discussionmentioning

confidence: 93%

The effect of soy or isoflavones on homocysteine levels: a meta‐analysis of randomised controlled trials

Song

Zeng

et al. 2016

J Human Nutrition Diet

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

The effect of soy or isoflavones on homocysteine levels: a meta‐analysis of randomised controlled trials

Song

Zeng

et al. 2016

J Human Nutrition Diet

View full text Add to dashboard Cite

show abstract

“…Although the systemic interactions between methionine/homocysteine and estrogen (its receptors) are complex and unclear (51), based on clinical investigations comparing pregnant, premenopausal and postmenopausal women with estrogen replacement therapy (ERT) with age-matched men and postmenopausal women without ERT, the 3 rd National Health and Nutrition Examination Survey has recognized the inverse relationship between serum estrogen and homocysteine (52). In line with that, randomized (placebo-)controlled trials also demonstrated that exogenous estrogen intervention in postmenopausal women inversely in uences homocysteine-methionine metabolism (53,54). However, vivid clinical investigations are lacking to address de nite relationships between methionine metabolism, estrogen and bone health.…”

Section: Discussionmentioning

confidence: 99%

Exhaled breath metabolites reveal postmenopausal gut-bone cross-talk and non-invasive markers for osteoporosis

Sukul,

Fischer,

Broderius

et al. 2024

Preprint

View full text Add to dashboard Cite

Menopause driven decline in estrogen exposes women to risk of osteoporosis. Detection of early onset and silent progression are keys to prevent fractures and associated burdens. In a discovery cohort of 120 postmenopausal women (aged: 49 – 90 years), we combined repeated quantitative pulse-echo ultrasonography of bone, assessment of grip strength and serum bone markers with mass-spectrometric analysis of exhaled metabolites to find breath volatile markers and quantitative cutoff levels for osteoporosis. Obtained markers and cutoffs were validated in an independent cohort of 49 age-matched women with 6 months apart seasonal follow-ups. Within the discovery cohort median concentrations (ppbV) of exhaled end-tidal dimethyl sulfide (DMS), allyl-methyl sulfide, butanethiol and butyric acid increased significantly (p≤0.005) by 45.24%, 42.83%, 38.29% and 33.66% in subjects (n=27) with bone density at high-risk of osteoporosis and fracture, when compared to subjects (n=62) with normal bone mineral density (BMD). Increased age and decreased grip strength were concomitant. All these changes were reproduced within the independent validation cohort including seasonal follow-ups. Exhaled metabolite expressions remained age independent in either cohort. Serum bone markers showed random expressions without any reproducibility. DMS exhalations even differed between patients with recent (<1 year), old and without fractures. Metabolite exhalations and BMDs were down-regulated during winter mirroring the regional climate change. ROC analysis in the discovery cohort yielded high classification accuracy (AUC=0.86) of DMS with a cutoff at 15.88 ppbV for osteoporosis, which predicted subjects at high-risk within the independent validation cohort with high (>91%) sensitivity and specificity during both follow-ups. Non-invasive analysis of exhaled DMS allowed more reliable classification of osteoporosis risk than conventional serum bone markers. We identified associations of exhaled organosulfur and short-chain fatty acid markers to bone metabolism in postmenopausal osteoporosis via a gut-bone axis.

show abstract

“…Rats were divided into equal groups after two weeks of ovariectomy as follow: Group I: Intact rats served as a control (I) Group II: Ovariectomized rats served as a control (II) Group III: Ovariectomized rats received daily 2mg of conjugated estrogen orally, Cagnacci, A. et al (2006).…”

Section: Experimental Procedurementioning

confidence: 99%

The Effect of Folic Acid Supplementation on Osteoporotic Markers in Ovariectomized Rats.

Al-Sowyan

Mahmoud

2010

Egyptian Academic Journal of Biological Sciences. C, Physiology

View full text Add to dashboard Cite

Menopause is considered to be a natural change of life, which may be accompanied by various health problems such as osteoporosis and fracture. This study is designed to assess the effect of estrogen treatment, folic acid supplementation on bone markers in ovariectomized (ovx) rats. Fifty adult female rats were divided into five equal groups: one served as control, the rats in the second group were subjected to ovariectomy, the third group were exposed to ovariectomy and treated with estrogen, the fourth group were ovariectomized and supplemented with folic acid and the fifth group were consist of ovariectomized rats treated with estrogen and supplemented with folic acid. Ovariectomized rats showed insignificant increase in serum ca+2 and osteocalcin levels with significant decrease in serum vitamin D3 (vit.D3) and significant increase in alkaline phosphates activity and homocysteine levels. Estrogen treatment of ovariectomized rats showed a significant decrease in serum homocysteine (Hcy) levels, alkaline phosphates activity accompanied with insignificant decrease in serum ca+2, vit.D3 and osteocalcin than ovariectomized rats. Supplementation of folic acid to ovariectomized rats induced significant increase in osteocalcin and decreased Hcy levels, insignificant changes in serum ca+2, vit. D3 and alkaline phosphates than ovariectomized control rats, while combined treatment of ovariectomized rats with estrogen and folic acid exhibit better action on bone turnover with marked decrease in Hcy level. So, we can conclude that, supplementation of folate with estrogen treatment has a beneficial effect for menopausal women to avoid osteoporosis and fracture.

show abstract

Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women

Abstract: Low- or high-dose HT similarly influences fasting homocysteine levels. Low-dose HT seems to be more effective than high-dose HT in reducing the post-methionine homocysteine increase.

Cited by 10 publications

References 40 publications

The effect of soy or isoflavones on homocysteine levels: a meta‐analysis of randomised controlled trials

The effect of soy or isoflavones on homocysteine levels: a meta‐analysis of randomised controlled trials

Exhaled breath metabolites reveal postmenopausal gut-bone cross-talk and non-invasive markers for osteoporosis

The Effect of Folic Acid Supplementation on Osteoporotic Markers in Ovariectomized Rats.

Contact Info

Product

Resources

About